Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 84,34 € (-3,49 %). Medianen er 89,33 € (+2,22 %).
| Køb |
11 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline
Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Mere på de.investing.com
Kiniksa Pharmaceuticals reaches record high at $64.85
Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Mere på de.investing.com
Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%
Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Mere på de.investing.com
Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance
Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Mere på de.investing.com
Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket
Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 252,47 mio. | 63,82 % |
| Bruttofortjeneste | 134,53 mio. | 62,32 % |
| Nettoresultat | 41,8 mio. | 166,08 % |
| EBITDA | 52,57 mio. | 124,01 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 6,86 mia. € |
Antal aktier | 78,57 mio. |
Højeste/laveste i 52 uger | 90,06 € - 33,57 € |
| Udbytte | Nej |
Beta | 0,08 |
P/E (PE Ratio) | 67,36 |
PEG (PEG Ratio) | 0,35 |
K/I (PB Ratio) | 10,61 |
P/S (PS Ratio) | 8,00 |
Virksomhedsprofil
Kiniksa Pharmaceuticals, Ltd., et biofarmaceutisk selskab, fokuserer på at opdage, erhverve, udvikle og kommercialisere terapeutiske lægemidler til patienter, der lider af invaliderende sygdomme med betydelige, uopfyldte medicinske behov verden over. Selskabets produktkandidater omfatter ARCALYST, en interleukin-1alpha- og interleukin-1beta-hæmmer, til behandling af recidiverende perikarditis, som er en inflammatorisk kardiovaskulær sygdom; Mavrilimumab, en monoklonal antistofhæmmer, der har gennemført fase II-kliniske forsøg til behandling af giant cell arteritis; Vixarelimab, et monoklonalt antistof, der er i et fase 2a-klinisk forsøg til behandling af prurigo nodularis, en kronisk inflammatorisk hudsygdom; og KPL-404, en monoklonal antistofhæmmer af CD40-CD154-interaktionen, et T-celle-costimulatorisk signal, der er afgørende for B-cellemodning, immunglobulinklasseskift og type 1-immunrespons. Kiniksa Pharmaceuticals, Ltd. blev stiftet i 2015 og har hjemsted i Hamilton, Bermuda.
| Navn | KINIKSA A BE-,000273235 |
| CEO | Sanj K. Patel |
| Hjemsted | London,
gl Bermuda |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 25.05.2018 |
| Medarbejdere | 366 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | KNSA |